Articles
| Open Access |
DOI: Lupus Nephritis In Systemic Lupus Erythematosus
Nazarova Nigina Otabek Qizi , Assistant, Department Of Faculty And Hospital Therapy No. 2, Tashkent Medical Academy, Tashkent, Uzbekistan Jabbarov Azim Atakhanovich , Associate Professor, MD, Department Of Faculty And Hospital Therapy No. 2 Tashkent Medical Academy, Tashkent, Uzbekistan Abduhalikova Nigora Fahriddinovna , Trainee Researcher, Normal And Pathological Physiology Tashkent Medical Academy, Tashkent, Uzbekistan Madazimova Dilrux Xayotjonovna , Assistant, Department Of Faculty And Hospital Therapy No. 2 Tashkent Medical Academy, Tashkent, UzbekistanAbstract
The pathogenesis, clinic, and treatment of kidney damage in patients with systemic lupus erythematosus (SLE) are considered. It is noted that if at the beginning of the disease signs of kidney damage are present in 25-50% of SLE patients, then later they are detected in almost 60% of adults and 80% of children. Variants of kidney damage in SLE are described.
The pathogenesis of SLE is generally considered on the model of lupus nephritis. The morphological classification of lupus nephritis, features of the main nephrological syndromes, and clinical variants (active and inactive) are presented. It is indicated that the treatment strategy depends on the activity of the disease, the clinical and morphological variant of lupus nephritis.
Keywords
SLE, lupus nephritis, immune response
References
Tareeva I. E., Krasnova T. N. kidney Damage in systemic lupus erythematosus. Nephrology. A guide for physicians. Ed. by I. E. Tareeva, M.: Medicine, 2000.
Vu T. V., Escalante A. a comparison jf quality of life of patients with systemic lupus erythematosus. J Revmatol 1999; 26: 2595–601.
Trager J., Ward M.M. Mortality and causes of death in systemic lupus erythematosus. Current Opinion in Rheumatology 2001; 13: 345–51.
Cervera R., Khamashta M.A., Font J. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. Medicine 2003; 82(5): 299–308.
Cameron J. S. Lupus nephritis and its management in 2001. In: Advances in Nephrology. Edited By N. A. Mukhina, Moscow: Russian doctor, 2001; 145-64.
Tareeva I. E., Shilov E. M., Krasnova T. N., etc. Lupus nephritis in the mid-twentieth and early twenty-FIRST century. Ter arch 2001; 6: 5-10.
Meteleva N. A., Kozlovskaya N. L. kidney Damage in antiphospholipid syndrome. Ter arch 2004; 9: 91-6.
Mukhin N. A., Kozlovskaya L. V., Kozlovskaya N. L. et al. Primary antiphospholipid syndrome – "venous" and "arterial" variants of the course. In the book: Clinical discussions. Internal disease. Edited By N. A. Mukhin, M.: Litterra, 2005; 261-77.
Stenina O. A., Sorokin E. V., Fomicheva O. A., etc. Prevalence and risk factors of atherosclerosis in patients with systemic lupus erythematosus. Cardiology 2005; 11: 105-8.
Cao A. N., Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Current Opinion in Rheumatology 2003; 15: 519–27.
Kohler H.P., Futers T.S., Grant P.J. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999; 81(4): 511–5.
Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis and rheumatism 1999; 42(2): 338-46.
Shilov E. M. Lupus nephritis: strategy and treatment. Ter arch 2006; 5: 76-85.
D’Crus. Mycophenolate mofetil of systemic vasculitis. Lupus 2005; 14: 55–7.
Chan T., Tse K., Tang C. et al. Long-term study of micophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Am J Soc Dis 2005; 16: 1076–84.
Cune W. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005; 353: 2282–4.
Article Statistics
Copyright License
Copyright (c) 2020 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.